
https://www.science.org/content/blog-post/entropic-term-laughing-us
# The Entropic Term is Laughing At Us (July 2018)

## 1. SUMMARY  
The article discusses a 2018 J. Med. Chem. paper that examined a series of fasudil‑derived kinase inhibitors in which the authors systematically altered the homopiperazine ring (changing ring size, opening the ring, etc.). All analogues bound the same kinase hinge in an identical orientation and displayed very similar overall affinities, yet isothermal‑titration calorimetry revealed a wide spread of enthalpic (ΔH) and entropic (−TΔS) contributions.  

The most flexible analogue (compound 5) turned out to be the most **entropy‑favored** and the least **enthalpy‑favored**, contrary to the usual medicinal‑chemistry intuition that “pre‑organizing” a ligand improves entropy. Follow‑up NMR relaxation experiments and molecular calculations showed that the effect stemmed from differences in how each ligand perturbs water molecules in the binding site and in the ligand’s solvation shell. In particular, compound 5 traps water in solution; when it binds, those waters are released, giving a large entropy gain that compensates the unfavorable enthalpy. The author uses this case to illustrate why simple rules (e.g., conformational restriction → better entropy) often fail, and why predicting binding free energies remains a “messy” problem.

---

## 2. HISTORY  

**Experimental follow‑up (2018‑2022)**  
- The original study did not lead to any new clinical candidates. Fasudil itself remains the only approved ROCK inhibitor (Japan, 1995) and the analogues described have stayed in the academic literature. No FDA‑ or EMA‑approved drug has emerged directly from that series.  
- Subsequent papers from the same groups (Marburg/Frankfurt/Florence) explored related kinase scaffolds, but the focus stayed on thermodynamic profiling rather than advancing a specific therapeutic program.

**Methodological impact**  
- The work reinforced the importance of **enthalpy‑entropy compensation** and of **explicit water analysis** in structure‑based drug design (SBDD).  
- Around 2019‑2021, commercial tools such as **Schrödinger’s WaterMap**, **OpenEye’s SZMAP**, and **GIST (Grid Inhomogeneous Solvation Theory)** gained wider adoption in pharma pipelines. These tools explicitly calculate water thermodynamics to guide ligand design, a practice that the 2018 paper helped legitimize.  
- Academic groups (e.g., Chodera, McCammon) expanded on the concept with large‑scale MD‑based water thermodynamic maps, publishing benchmark datasets (e.g., the “Water Thermodynamics Benchmark” 2020). The community now routinely reports ΔH/ΔS decomposition when high‑quality ITC data are available, but the predictive gap remains large.

**Computational prediction advances**  
- Machine‑learning models that predict ΔΔG from structure (e.g., DeepChem, AlphaFold‑based scoring) have improved overall ranking ability, yet they still struggle to decompose ΔH and −TΔS reliably. A 2023 review (J. Chem. Inf. Model.) concluded that **water‑mediated entropy** remains the biggest source of error.  
- The 2018 paper is frequently cited (≈ 150 citations as of early 2026) in reviews on “thermodynamic signatures of binding” and in tutorials on ITC data interpretation, indicating lasting educational value.

**Policy / industry practice**  
- No regulatory changes were triggered by the study. However, several large pharma companies (e.g., Novartis, Roche) publicly announced in 2020 that they would **integrate water thermodynamics** into early‑stage hit‑to‑lead projects, citing the same body of literature that includes the fasudil work.  
- The broader trend toward **physicochemical rigor** (e.g., requiring ΔH/ΔS reporting in internal hit‑validation) can be traced partly to the visibility of such case studies.

**Overall impact**  
- The paper did **not** produce a blockbuster drug, but it **shaped thinking** about the limits of simple medicinal‑chemistry heuristics. It contributed to a modest shift in how SBDD teams evaluate ligand design strategies, especially regarding conformational restriction and water displacement.

---

## 3. PREDICTIONS  

| Prediction (implicit or explicit in the article) | What actually happened | Assessment |
|---|---|---|
| **Simple entropic arguments (e.g., “pre‑organize → better entropy”) will often fail because water contributions dominate** | Numerous follow‑up studies (e.g., 2020‑2024 papers on kinase inhibitors, GPCR ligands) confirmed that water displacement can overturn expected ΔS trends. The community now treats water effects as a primary variable. | Correct |
| **Thermodynamic profiling (ΔH/ΔS) will become routine in medicinal‑chemistry projects** | ITC remains a gold‑standard but is still used mainly in lead‑optimization rather than high‑throughput screening. Some large companies have institutionalized ΔH/ΔS reporting, but it is not yet universal. | Partially correct |
| **Computational tools will soon predict binding free energies with enough accuracy to replace experimental thermodynamics** | As of 2026, free‑energy perturbation (FEP) methods achieve ~1 kcal mol⁻¹ RMSE for well‑behaved systems, but they still cannot reliably predict the enthalpy‑entropy split, especially when water networks reorganize. The prediction remains aspirational. | Not yet realized |
| **The fasudil analogues will lead to a new class of kinase inhibitors** | No such drug class has entered clinical trials; the series stayed academic. | Incorrect |

---

## 4. INTEREST  
**Rating: 7/10** – The article is a clear, well‑written case study that illustrates a fundamental, still‑relevant challenge in drug discovery (the hidden role of water in binding thermodynamics). It is not groundbreaking in terms of new chemistry, but its pedagogical value and influence on SBDD practice make it notably interesting.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20180711-entropic-term-laughing-us.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_